company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,697954.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1226876.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1924830.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1924830.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,581305.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,20978.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,319385.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-240942.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2165772.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2165772.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2165772.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,871567.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3037339.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1700000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.78
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1700000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.78
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1708129.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q2,2010-04-01,2010-06-30,2011-08-12 16:18:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.78
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1531275.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1332327.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2863602.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2863602.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,607462.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,15218.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1835322.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2427566.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5291168.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5291168.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5291168.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,881146.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6172314.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1700000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.61
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1700000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.61
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1708129.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2010.0,Q3,2010-07-01,2010-09-30,2011-11-14 16:57:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.61
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3337514.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3449941.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6787455.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6787455.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,112527.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,67524.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-45003.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6832458.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6832458.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6832458.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6832458.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,17500000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,17500000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,17641543.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:58:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3013555.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5329531.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8343086.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8343086.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,331803.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,70171.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-261632.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8604718.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8604718.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8604718.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8604718.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,17600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.49
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,17600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.49
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,17729216.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 11:30:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.49
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3271184.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7290554.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10561738.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10561738.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,334692.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,27673.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,748259.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,441240.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10120498.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10120498.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10120498.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10120498.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21100000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.48
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21100000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.48
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21063714.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q3,2011-07-01,2011-09-30,2012-11-09 14:36:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.48
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4343747.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8362974.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,912000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13618721.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13618721.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,334978.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,43632.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-259.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-291605.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13910326.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13910326.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13910326.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13910326.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19400000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.67
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19400000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.67
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19409000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.67
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5111000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4635000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,831000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10577000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10577000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,286000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-802000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1088000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11665000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11665000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11665000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11665000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.55
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.55
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21246000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 14:38:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.55
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7748000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5449000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,546000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13743000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13743000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,171000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-13000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-184000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13927000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13927000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13927000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13927000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22100000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.63
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22100000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.63
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22186000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:43:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.63
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8163000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6522000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14686000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14686000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,159000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-29000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-188000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14874000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14874000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14874000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14874000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.59
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.59
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25360000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 14:02:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.59
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13055000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8558000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-12000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21601000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21601000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,321000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,162000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-39000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-198000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21799000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21799000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21799000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21799000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,23600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.87
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.87
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23563000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.87
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1231000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1231000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,183000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,183000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1048000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13220000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5775000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18996000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17948000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,148000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-46000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-194000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18142000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18142000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18142000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18142000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28300000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.64
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28300000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.64
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28337000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 14:12:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.64
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6490000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6490000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,727000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,727000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5763000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,16849000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7618000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24468000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18705000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,114000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-78000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-192000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18897000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18897000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18897000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18897000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.66
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.66
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28836000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q2,2013-04-01,2013-06-30,2013-08-09 12:43:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.66
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16330000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16330000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1750000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1750000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14580000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18843000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7892000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26736000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12156000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,100000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-47000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-147000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12303000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,164000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12467000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12467000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12467000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29000000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.43
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29000000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.43
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29051000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q3,2013-07-01,2013-09-30,2013-11-08 14:02:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.43
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24495000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24495000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2359000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2359000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22136000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,27170000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8503000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35674000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13538000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,360000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,269000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-40000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-131000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13669000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,183000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13852000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13852000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13852000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28900000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.46
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28900000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.46
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28883000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.46
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,26973000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,26973000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2664000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2664000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,24309000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31778000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7904000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39683000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15374000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,71000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-107000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-178000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15552000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,224000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15776000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15776000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15776000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29411000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q1,2014-01-01,2014-03-31,2014-05-09 14:12:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,36014000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,36014000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4158000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4158000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,31856000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,32330000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8942000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41272000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9416000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,70000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-31000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-101000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9517000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,105000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9622000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9622000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9622000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.33
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.33
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29494000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q2,2014-04-01,2014-06-30,2015-08-17 17:09:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.33
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,43674000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,43674000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3783000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3783000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,39891000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31440000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10438000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41878000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1987000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3175000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-511000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3686000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5673000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,198000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5871000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5871000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5871000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29400000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29400000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28973000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:15:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,51712000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,51712000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3765000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3765000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,47947000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,37167000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10701000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,47872000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,75000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6621000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,246000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1444000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7819000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7744000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,372000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8116000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8116000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8116000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.28
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.28
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29079000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.28
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,59384000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,59384000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11838000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11838000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,47546000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,46928000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9798000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,56726000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9180000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6931000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,485000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6446000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15626000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,199000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15825000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15825000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15825000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28800000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.55
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28800000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.55
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28529000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q1,2015-01-01,2015-03-31,2016-05-16 16:13:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.55
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,64197000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,64197000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13997000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13997000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,50200000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,42672000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12471000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,55143000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4943000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7069000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1116000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5953000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10896000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,254000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11150000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11150000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11150000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28582000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:01:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,67303000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,67303000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14486000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14486000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,52817000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,43923000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11282000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,55205000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2388000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7113000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,30000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7083000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9471000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,300000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9771000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9765000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9765000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28700000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.34
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28700000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.34
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28681000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 17:30:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.34
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,49003000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,49003000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12011000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12011000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,36992000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,54356000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11311000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,65667000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-28675000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6492000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-410000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6902000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-35577000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1016000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-36593000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-36599000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-36599000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28800000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.27
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28800000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.27
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28712000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.27
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,35716000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,35716000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14966000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14966000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20750000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,39690000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9880000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1700000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,28313000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,79583000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-58833000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7202000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,738000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6464000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-65297000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,257000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-65554000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-65554000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-65554000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29500000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.22
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29500000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.22
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29471000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q1,2016-01-01,2016-03-31,2016-05-16 16:13:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.22
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,44530000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,44530000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,23063000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,23063000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21467000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40425000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10675000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,9600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,51000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,70000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,60821000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-39354000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7449000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,223000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7226000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-46580000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,229000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-46809000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-46809000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-46809000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29400000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.59
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29400000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.59
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29504000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q2,2016-04-01,2016-06-30,2016-08-09 16:01:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.59
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,35387000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,35387000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13838000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13838000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21549000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,27827000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9940000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2421000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,126000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,40314000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18765000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7720000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,165000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7555000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26320000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,246000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26566000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.9
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29600000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.9
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29525000.0
Aegerion Pharmaceuticals Inc,AEGR,549300PFYFSCKFOY5J36,0001338042,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 17:30:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.9
